View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 18, 2022

Genexine doses first subject in Phase II HNSCC combination therapy trial

The trial will analyse and assess the safety and efficacy of the triple combination treatment in R/M HNSCC patients.

Genexine has dosed the first subject in the Phase II clinical trial of triple combination therapy in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). 

The combination treatment comprises the company’s two drugs GX-188E and GX-I7, along with Opdivo (nivolumab).

Being carried out in South Korea, the trial will assess the safety and efficacy of the triple combination treatment in 21 subjects with HPV-16 or 18-positive recurrent/metastatic (R/M) HNSCC. 

In the trial, endpoints evaluated will include those linked to safety and efficacy such as the overall rate of response.

A long-acting interleukin 7, immuno-oncology drug, GX-I7 enhances absolute lymphocyte counts to boost the number of T cells. It also has a mechanism for penetrating into the tumour microenvironment. 

GX-188E is an anticancer, therapeutic deoxyribonucleic acid (DNA) vaccine and could specifically target HPV antigens to dendritic cells. 

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor of Bristol Myers Squibb.

Genexine president and CEO Neil Warma said: “This study is very important for Genexine as it represents a unique approach to treating a very complicated and difficult cancer. 

“We are running separate trials with GX-188E in cervical cancer and GX-I7 in triple-negative breast cancer and glioblastoma, but the idea to combine both with a checkpoint inhibitor in HNSCC could challenge the standard of care and truly provide an important alternative for these patients and possibly to numerous other HPV related cancers.”

R/M HNSCC is regarded as an incurable disease, with a reduced prognosis and a few options for treatment. 

As the tumour cells grow in the oropharyngeal region, it substantially affects the lives of patients, leading to functional disability and an increased death rate.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena